<DOC>
	<DOCNO>NCT01116089</DOCNO>
	<brief_summary>The purpose study assess pharmacokinetic safety comparability Bramitob® administer inhalation use PARI eFlow® rapid electronic nebulizer v PARI LC® PLUS nebulizer Cystic Fibrosis Patients infect Pseudomonas Aeruginosa</brief_summary>
	<brief_title>Pharmacokinetic Study Bramitob® Administered Inhalation PARI eFlow® v PARI LC® PLUS Nebulizer</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Main inclusion Criteria : Patients either sex age ≥ 18 year ; Clinical diagnosis cystic fibrosis ( patient register National Registry cystic fibrosis document , applicable , depend country legislation ) ; Positive response ( sweat chloride concentration ≥ 60 mmol/l ) standard sweat test document clinical record sweat chloride concentration ≥ 40 mmol/l least two gene mutation consistent CF document clinical record ; Chronic colonization Pseudomonas aeruginosa FEV1 ≥ 35 % predict normal value calculate accord recommendation Official Statement European Respiratory Society American Thoracic Society Main exclusion Criteria : Evidence impair renal function ( serum creatinine level ≥ 1.5 mg/dl ) ; Evidence impair auditory function ( auditory threshold either ear 20 dB frequency 250 8000Hz ) ; Sputum culture contain Burkholderia cepacia ; Received loop diuretic within 7 day study drug administration ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Cystic fibrosis , tobramycin , nebulizer , PK</keyword>
</DOC>